Welcome to the highly anticipated Adoptive T-Cell Therapy Summit Europe Edition to be in London. The only conference in Europe dedicated specifically to the 3 core Adoptive T-Cell Therapies we will give you access to the very latest clinical progress and exclusive case studies. Join us and hear experts discuss and debate the most exciting findings, case studies, keynote presentations and clinical trials in an immersive environment coupled with unrivalled networking opportunities with industry leaders.
For more information *http://www.tcellsummit.com
The Adoptive T-cell Therapy Summit will bring together leaders from Pharmaceuticals, Biotech, Academia and the wider community to further the advance and development of T-cell therapies.
T- Cell Therapy has grown leaps and bounds in these few years, CD19 CAR T therapy has shown how effective and efficient it can be however significant challenges remain, some of the main challenges: –
SAFETY – Toxicity avoidance: methods for turning off rogue T cells vs. using short-term gene expression with mRNA RELAPSE – Understanding and dealing with relapse from treatment. The exact mechanisms that contribute to tumour relapse remain largely unclear ANTIGEN – Determining what antigen is suitable for what tumour. SIDE EFFECTS – Managing side effects including cytokine release syndrome (sCRS) – and overload defence cells, symptoms of fever, hypotension and neurotoxicity due to sCRS.
Join experts from pharmaceuticals, universities and biotechnology discuss the most pressing issues in adoptive T-cell Therapies for cancer by examining techniques to improve effectiveness and success rate.
Delegates will learn how university collaboration with businesses in the field of CAR-T, TCT’s andTIL including advancement in T-Cell engineering. Efficacy in difference cancer models and results in human clinical studies. With in depth case studies on solid and liquid tumours coupled with expert diagnosis and analyse.
We will examine the development of clinical trials and the commercialisation of T-Cell therapies. Delegates will have the opportunity to better grasp the future challenges of advanced T-cell therapies including the ever evolving regulatory landscape and the transfer of T-cell therapies into commercial products.
Our world class speakers will provide you with cutting edge case studies, clinical trials and keynotes to address the latest and future trends and research. With unrivalled networking opportunities in an interactive and immersive environment designed for both scientific and business discussions.
TAKE ACTION NOW
Don’t miss the opportunity join us to discuss the future of T-Cell Therapies, due to this event being highly anticipated, it’s strictly a first come first come base – limited places available